Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures
The use of novel synthetic cannabinoids as intoxicants continues in spite of associated health risks. These compounds are typically smoked or vaporized, but many synthetic cannabinoids contain thermally labile chemical moieties. This study investigated the thermal stability of six carboxamide-type synthetic cannabinoids (CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18) in order to characterise potential user exposure to thermolysis products.
Compounds were heated sequentially to 200, 400, 600 and 800 °C using a thermolysis probe, and the resultant thermolysis products were analysed via gas chromatography–mass spectrometry. A secondary analysis quantified thermolytically generated cyanide via liquid chromatography–tandem mass spectrometry.
All six synthetic cannabinoids underwent thermal degradation when heated above 400 °C, and released a variety of potentially toxic products, including toluene, naphthalene, and 1-naphthalamine. Compound-specific degradants were tentatively identified together with general degradative pathways for carboxamide-type synthetic cannabinoids, which proceed via indole- or indazole-amide formation and subsequent dehydration to an indole- or indazole-carbonitrile. These degradative pathways culminated in the thermolytic liberation of cyanide, in amounts up to 27 µg per mg of starting material.
People who smoke carboxamide-type synthetic cannabinoids are likely to be exposed to a range of potentially toxic thermal degradants, including cyanide. These degradants could have significant health impacts in human users.
KeywordsSynthetic cannabinoids Toxicity Carboxamides Thermolytic products Cyanide Degradants
This work was supported by research grant funding to BFT from the National Institute on Drug Abuse (1R01DA-040460), and to JLW from the National Institutes of Health (DA-03672). ISM was supported by a National Health and Medical Research Council Fellowship.
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest to declare.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M (2015) Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci 6:1546–1559CrossRefGoogle Scholar
- 3.Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson AL, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR (2005) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg Med Chem 13:89–112CrossRefGoogle Scholar
- 4.Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JBC, Glass M, McGregor IS, Connor M, Kassiou M (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7:1241–1254CrossRefGoogle Scholar
- 15.Grigoryev A, Kavanagh P, Melnik A, Savchuk S, Simonov A (2013) Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol 37:265–276Google Scholar
- 25.Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF (2018) Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. J Pharmacol Exp Ther 365:437–446CrossRefGoogle Scholar
- 26.EMCDDA (2014) Annual report on the implementation of council decision 2005/387/JHA. http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf. Accessed Nov 2017
- 28.Mottier N, Jeanneret F, Rotach M (2010) Determination of hydrogen cyanide in cigarette mainstream smoke by LC/MS/MS. J AOAC Int 93:1032–1038Google Scholar
- 32.Simeonova FP, Fishbein L, World Health Organization (2004) Hydrogen cyanide and cyanides: human health aspects. http://www.who.int/ipcs/publications/cicad/en/cicad61.pdf. Accessed Dec 2017
- 37.Anonymous (2017) A look so far into my use of FUB-AMB. https://www.reddit.com/r/researchchemicals/comments/4dre6j/a_look_so_far_into_my_use_of_fubamb/. Accessed Dec 2017
- 38.Lundquist P, Rosling H, Sörbo B, Tibbling L (1987) Cyanide concentrations in blood after cigarette smoking, as determined by a sensitive fluorimetric method. Clin Chem 33:1228–1230Google Scholar
- 39.Åstrand A, Vikingsson S, Lindstedt D, Thelander G, Gréen H, Kronstrand R, Wohlfarth A (2018) Metabolism study for CUMYL-4CN-BINACA in human hepatocytes and authentic urine specimens: free cyanide is formed during the main metabolic pathway. Drug Test Anal. https://doi.org/10.1002/dta.2373 Google Scholar